While demand for A2 infant formula has rebounded from a pandemic-sparked collapse of the Chinese daigou - or reseller - market in 2020, Synlait had been pinning its hopes on a mysterious “customer S”, widely believed to be US nutrition giant Abbott, which was expected to dominate its New Zealand production. But details about a deal with the yet to be named customer have yet to be released. But chief financial officer Rob Stowell said late last month that raw material inventory was up 62 per cent, in part from “customer S preparation”.
An extract from Today's Australian.
It would appear the Synlait Trading halt is not related to A2 Milk.
While demand for A2 infant formula has rebounded from a...
-
- There are more pages in this discussion • 1,947 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.60 |
Change
-0.040(0.60%) |
Mkt cap ! $4.800B | |||
| Open | High | Low | Value | Volume |
| $6.58 | $6.61 | $6.57 | $1.213M | 184.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 12079 | $6.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.60 | 5513 | 12 |
View Market Depth
| Last trade - 10.18am 08/08/2024 (20 minute delay) ? |
| A2M (ASX) Chart |